Week in Review: Cannabis & Psychedelics Industry Highlights

LOS ANGELES – The past two weeks brought measurable movement across federal policy, corporate financial reporting, international deals, and product categories in the U.S. Cannabis sector. Operators absorbed details on rescheduling implications, watched hemp-derived THC face tighter constraints, and reviewed strong first-quarter earnings from major players. Psychedelic research added another data point that politicians can no longer afford to ignore. All while a clock on an entire hemp category kept ticking louder.

What follows is HCN’s read of the fortnight: the headlines that moved the market, the regulatory updates demanding immediate action, the mergers and acquisitions reshuffling the board, and the signals buried in financial filings that reward close attention.

1. Rescheduling Lands & the Fine Print Matters More Than the Headlines

The Department of Justice placed state-licensed medical Cannabis and FDA-approved Cannabis-based products into Schedule III. This order opens a pathway for 280E tax relief on qualifying medical operations while adult-use markets stay in Schedule I.

The DEA launched a federal registration portal for medical Cannabis dispensaries, giving operators a 60-day window to file and secure protected status during review.

Industry observers note the practical requirements of Schedule III compliance, which include pharmaceutical standards for manufacturing, testing, and documentation. This step represents targeted progress for medical operators rather than broad deregulation. Retrospective tax considerations and IRS guidance will shape financial outcomes in the coming months.

2. The Hemp Clock Has No Snooze Button

Congressional efforts to delay or adjust the upcoming hemp THC limits collapsed in committee processes. The November deadline moves closer, creating supply chain adjustments and inventory planning challenges for manufacturers and retailers.

Target expanded its hemp-derived THC beverage sales footprint, showing continued retail interest in compliant formats even as regulatory pressure builds.

In an action separate from rescheduling, the DEA assigned a specific Schedule I listing and drug code to hexahydrocannabinol (HHC), which had occupied a gray zone for several years and was marketed alongside delta-8 and delta-10 THC products in a category that grew significantly following the 2018 Farm Bill.

These dynamics separate hemp-derived products from the core plant Cannabis market and forces businesses to evaluate positioning in wellness and beverage segments under new boundaries.

3. Q1 2026 Earnings Season Launched

The first quarter of 2026 brought a wave of financial reporting from major operators, and the picture that emerges is of an industry executing under structural pressure without the benefit of federal clarity it was widely promised.

Curaleaf, Trulieve, Verano, Green Thumb Industries, TerrAscend, RYTHM, SNDL, and LEEF Brands each reported figures that highlighted disciplined cost management and market share gains in key states.

The collective takeaway from Q1 2026 is that operators have internalized the current environment. The question rescheduling now opens is whether the 280E relief will translate into a meaningful reallocation of capital toward debt reduction, margin improvement, or the M&A that the stronger players have been positioning to execute.

4. Consolidation & Expansion Moves

Vireo announced it will acquire FLUENT in an all-stock deal, adding Florida market exposure to a company that has been systematically building its multi-state footprint.

Curaleaf secured full control of Germany’s Four 20 Pharma. Germany’s medical Cannabis program is generating real revenue, and Curaleaf’s decision to consolidate ownership of its German vehicle signals a long-term commitment to the European market rather than an exploratory position.

Internationally, High Tide strengthened its German position through Remexian distribution, adding to the evidence that North American operators with credible European strategies are finding real commercial traction in a German market that has moved faster than many observers expected.

Cannara Biotech completed its acquisition of Medican Organic, a Canadian transaction that consolidates production capacity at a time when supply economics continue to compress margins across North American markets.

On the professional services side, Aprio acquired Price Kong in a move specifically targeting the Cannabis sector. Price Kong has been one of the more prominent accounting firms serving Cannabis operators, and its absorption into Aprio’s national platform signals that the ancillary professional services market (accounting, tax advisory, compliance) is consolidating in parallel with the operators it serves.

5. Psychedelics Policy & Research Developments

The political conversation around psychedelic therapy is no longer a fringe discussion in Washington. Congress formally pressed the FDA on psychedelic therapy approvals, with lawmakers pushing for regulatory clarity on the path to market for psilocybin, MDMA, and related compounds.

That congressional pressure came at the same time as new clinical findings on the potential benefits of psilocybin for individuals with nicotine dependence.

Helus Pharma and TARA Mind announced a collaboration focused on veteran mental health, targeting the psychedelic-assisted therapy space for a population, veterans with treatment-resistant PTSD and depression, where the human cost of therapeutic inaction is well documented.

6. Market Projections & Operational Updates

LeafLink released its 2026 Wholesale Cannabis Pricing Guide, providing the most comprehensive current snapshot of B2B pricing conditions across state markets. In a sector where wholesale price compression has been one of the dominant financial themes for several years, the guide offers operators and investors a grounded view of where unit economics actually stand. Useful context for reading the Q1 2026 earnings filings alongside.

Allied Market Research projected the global Cannabis market will reach $149 billion by 2031, a figure that reflects continued international market development, pharmaceutical Cannabis expansion, and the longer-term normalization of Cannabis in regulated consumer markets worldwide.

Hall of Flowers relocated its Northern California B2B trade event to Sacramento, a logistical shift that nonetheless carries some symbolic weight.

HCN Insight

The rescheduling order means real progress for qualifying medical operators. If IRS guidance confirms the 280E relief, it will change the financial math overnight for a significant portion of the industry. The DEA registration window is not a mere formality. It is functional. Operators who treat it as a paperwork exercise rather than a strategic priority will miss the first deliverable produced by rescheduling.

Meanwhile, the industry’s reflexive optimism remains its most persistent liability. The celebratory cycle triggered by headlines about rescheduling, with the actual requirements buried in paragraph twelve, produced years of misaligned capital allocation and companies built for a federal environment that never arrived on schedule. Schedule III is a pharmaceutical control category. It carries clinical trial obligations, IND submissions, manufacturing reproducibility standards, and dosage standardization requirements. Most state retail Cannabis operators were not built around these frameworks. The compliance work ahead is substantial.

On hemp, the window for a congressional fix has not closed completely, but it has nearly closed, and the industry cannot afford to plan as though rescue is coming. The operators who survive November 12 with their businesses intact will be those who made hard decisions in Q2 2026, not those who held out for an amendment that could not find a floor vote.

The psychedelics sector is operating on a different timeline but with gathering institutional momentum. Congressional pressure on the FDA, accumulating clinical data across multiple therapeutic applications, and the entry of credible pharmaceutical partners into the veteran mental health space all point to a category that is moving from the research phase toward the commercialization phase; deliberately, with regulatory friction, but moving.

The M&A activity tells the market something important. Operators and their advisors are betting on a more consolidated, more professionally managed sector going forward. That bet has been made before and lost before. But the conditions now (potential 280E relief, genuine international revenue streams, professional services consolidation) are different from the conditions that animated the 2019-2021 M&A cycle.

The companies that will define this industry in five years are the ones doing the harder work right now: reading the regulatory documents rather than the headlines, making compliance investments rather than press releases, and building for the market that actually exists rather than the one they were promised. The signals are there. Following them requires looking past the white noise.